Disease relevance of Stomatitis, Aphthous

• Nicotine patches for aphthous ulcers due to Behçet's syndrome [1].
• Thalidomide for aphthous ulcers in HIV infection [2].
• Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group [3].
• Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers [4].
• Thalidomide is used to treat human immunodeficiency virus (HIV)-associated conditions, including aphthous ulcers and wasting syndrome [5].

High impact information on Stomatitis, Aphthous

• Phenelzine in the treatment of aphthous ulcers of the mouth [6].
• Association of major aphthous ulcers and nicorandil [7].
• Aphthous ulcers of mouth from captopril [8].
• Use of levamisole in recurrent aphthous stomatitis [9].
• Whereas extraocular manifestations such as genital ulcerations, arthritis, and skin lesions remitted with IFN, only 36% of oral aphthous ulcers responded [10].

Chemical compound and disease context of Stomatitis, Aphthous

• METHODS: We performed a double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients [3].
• Does phenelzine relieve aphthous ulcers of the mouth [11]?
• Sucralfate suspension as a treatment of recurrent aphthous stomatitis [12].
• Treatment of recurrent aphthous stomatitis with pentoxifylline [13].
• Acyclovir in the prevention of severe aphthous ulcers [14].

Biological context of Stomatitis, Aphthous

• Polymorphisms in the IL-10 and IL-12 gene cluster and risk of developing recurrent aphthous stomatitis [15].

Anatomical context of Stomatitis, Aphthous

• The hypothesis tested was that aphthous ulcers may lack key extracellular matrix components, or their receptors, that are necessary for the migration of marginal keratinocytes from the ulcer edge [16].
• Thalidomide-resistant HIV-associated aphthae successfully treated with granulocyte colony-stimulating factor [17].
• Defining a T-cell epitope within HSP 65 in recurrent aphthous stomatitis [18].
• The present study evaluated the expression of CD54 and its ligand, CD11a (lymphocyte function-associated antigen, LFA-1) in oral lesions of lichen planus, recurrent aphthous stomatitis, secondary Sjögren's syndrome and traumatic ulceration using an immunoperoxide technique [19].
• We report a case of superior vena cava syndrome caused by Behçet's disease in a 40-year-old man with recurrent oral aphthous ulcers and skin rashes on the anterior chest wall [20].

Gene context of Stomatitis, Aphthous

• Recurrent aphthous stomatitis and gene polymorphisms for the inflammatory markers TNF-alpha, TNF-beta and the vitamin D receptor: no association detected [21].
• In particular, patients with oral aphthous ulcers (n = 51, 34 pg/ml) and neurological features (n = 4, 71 pg/ml) exhibited increased IL-8 levels [22].
• The levels of IL-4, IL-10 and IL-13 were found to be high in active BD patients, and IL-12 and interferon-gamma levels were lower in active BD patients than in inactive BD, recurrent aphthous stomatitis, and control patients [23].
• In this study, we investigated the levels of interleukin (IL)-4, IL-10, IL-12, IL-13 and interferon-g in the sera of patients with BD, in comparison with recurrent aphthous stomatitis and healthy controls, to determine the Th1/Th2 profile of the disease [23].
• No deviations of HLA-A and -B antigens in patients with recurrent aphthous stomatitis [24].

Analytical, diagnostic and therapeutic context of Stomatitis, Aphthous

• Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis [25].
• Minor recurrent aphthous stomatitis and smoking: an epidemiological study measuring plasma cotinine [26].
• This study was a double-blind placebo-controlled cross-over study of a 0.2% chlorhexidine gluconate mouthwash used 3 times daily on plaque, staining and candidal carriage in a group of recurrent aphthous ulcer suffers who maintained normal oral hygiene measures [27].
• Treatment options include no treatment, treatment of associated systemic diseases or conditions (eg, celiac sprue, vitamin deficiencies), systemic medications, topical medications, conversion of the aphthous ulcer to a wound, and palliative treatments [28].
• Human neutrophil-type (MMP-8) and fibroblast-type (MMP-1) interstitial collagenase, and their inhibition by tetracyclines in saliva from patients with recurrent aphthous ulcers (RAU) or aphthae, were studied by means of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and enzymological analyses [29].

References